European Association for the Study of the Liver Congress 2026 (EASL 2026)

Treatment with seladelpar for 4 years yields consistent biochemical efficacy, with no new safety concerns, among patients with cirrhosis and primary biliary cholangitis (PBC), as shown by interim results from the open-label ASSURE study.

Faecal microbiota transplantation (FMT) significantly improves alcohol abstinence and reduces relapse episodes for up to 6 months in patients with alcohol-related liver disease (ALD) and alcohol use disorder (AUD), as shown in a recent study presented at EASL 2026.

In the phase IIb/III EPICS-III study, the dual PPAR-α/γ agonist saroglitazar improves biochemical response (BCR) rates among individuals with primary biliary cholangitis (PBC) who had an inadequate response or intolerance to ursodeoxycholic acid (UDCA).